LONDON--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York.

Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA). The company announced favorable 6-month results from ...

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a market capitalization of $2.80 billion, a P/E ratio of 122.93 and a beta of 1.01.

LONDON - LivaNova PLC (NASDAQ:LIVN), a prominent medical technology company, today announced successful primary endpoint results for its OSPREY trial, which assesses the efficacy of the aura6000 ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep ...

LONDON - LivaNova PLC (NASDAQ:LIVN), a prominent medical technology company, today announced successful primary endpoint results for its OSPREY trial, which assesses the efficacy of the aura6000™ ...